Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)
Authors
Okines, A. F. C.Braybrooke, J.
MacPherson, I. R.
Sutherland, S.
Howell, Sacha J
Wheatley, D.
Waters, S.
Roylance, R.
Baird, R. D.
Oikonomidou, O.
Palmieri, C.
Harries, M.
Harper-Wynne, C.
Sheri, A.
Khan, S.
Bunce, C.
Mohammed, K.
Lee, D.
Turner, N. C.
Affiliation
The Royal Marsden NHS Foundation Trust, LondonIssue Date
2023
Metadata
Show full item recordCitation
Okines AFC, Braybrooke J, MacPherson IR, Sutherland S, Howell SJ, Wheatley D, et al. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005533.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS1111Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS1111Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS1111